More execution challenges, downgrading to SELL
Hansa recently announced the first results from its 2nd gen product, HNSA-5487, which did not actually give an answer to its repeat dosing potential and likely will not be clear even with all data analysed in 2024. While we believe that HNSA-5487 is the real value in the company, the lack of claritHansa Medical is a biopharmaceutical company focusing on novel immunomodulatory enzymes. The research project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Additional projects focus on development of new antibody modulating enzymes, as well as HBP, a diagnostic biomarker for prediction of severe sepsis at emergency departments that is already introduced on the market. Co.'s business consists of research and development for production of pharmaceuticals.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.